ClinicalTrials.gg
CompletedNCT03370770Updated Dec 24, 2020Results posted

Afatinib Osimertinib Sequencing NIS

An observational study in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Completed at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-24.

Sponsored by Boehringer Ingelheim · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
204
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim — 3 open to participants now, 5 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Boehringer Ingelheim.

Enrollment
9th of 16
204 · median 216
Started
2017
with 4 others
Observational
16 of 68
1 open now
Registered
56th of 68
by date

Among the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, this one is the 9th largest by enrollment of the 16 observational ones that give a count, is one of 5 that started in 2017, is one of 16 observational ones, and was the 56th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line treatment followed by osimertinib in case the T790M resistance mutation was developed.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study is planned that around 65 study centres in 11 countries will be participating in this noninterventional study and at least 190 consecutive eligible patients will be enrolled to the study. Every patient who fulfils inclusion and exclusion criteria and agree to participate in the study (if a written informed consent is required for this NIS by local regulation and legal requirement) will be selected until the required sample size is achieved.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)
  • The tumour harbours common EGFR mutations (Del19, L858R) at start of treatment
  • Patients who initiated second-line osimertinib treatment for acquired T790M mutation at least 10 months prior to data entry, AND who were treated with afatinib (Gi(l)otrif®) in the first-line
  • Patients treated with osimertinib within an EAP/CUP or regular clinical practice
  • Age ≥ 18 years
  • Signed and dated written per regulations (Exemption of a written informed consent for NIS based on existing data in countries per local regulations and legal requirements)

Exclusion criteria

Exclusion Criteria:

  • Patients who received drug(s) other than osimertinib as the treatment and/or patients who received drug(s) other than afatinib (Gi(l)otrif®) as the first-line treatment
  • Patients with active at start of treatment (either afatinib/Gi(l)otrif® or osimertinib)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
204 participants (actual)
Patient registry
No

Groups and cohorts

  • patients with EGFR mutation-positive NSCLC

    (Non-Small Cell Lung Cancer) (Epidermal Growth Factor Receptor)

    Drug: Afatinib · Drug: Osimertinib

Interventions

  • GILOTRIF, GIOTRIF, XOVOLTIB

  • on T790M resistance mutation was developed

06

What researchers measure

Primary outcomes

  1. Time on Treatment With Afatinib (Gi(l)Otrif®) Followed by Osimertinib

    Time on treatment, which was defined as time in months from the start date of Afatinib (Gi\[l\]otrif®) treatment ('start date of initial dose' for First-Line Treatment) to the end date of Osimertinib treatment (maximum between 'end date of initial dose' and the last 'end date of dose modification' for Second-Line Treatment) or death date due to any cause ('date of death'). Time on treatment (months) = Time on treatment (days)/30.4375. 'Time on treatment was analysed using Kaplan-Meier method, and the median along with two-sided 90% confidence interval was displayed using the Greenwood's formula for estimation of standard errors.

    Time frame: Data collected from start of treatment until data entry completion, up to 96.8 months for first analysis and up to 114.1 months for the extension analysis.

Secondary outcomes

  1. The Percentage of Participants With Different Types of Mutations After Categorisation

    Different types of resistance mutations identified at the time of discontinuation of osimertinib treatment were systematically reviewed and categorised.

    Time frame: Data collected from start of treatment until data entry completion; up to 96.8 months.

07

Results

Posted Dec 24, 2020
Limitations and caveats
This study has no comparator group limiting the interpretability of the results as they cannot be put into perspective.

Participant flow

Non-interventional, multi-centre cohort study based on existing data from medical records of patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC) treated with afatinib (Gi\[l\]otrif®) as first-line treatment followed by osimertinib in case the T790M resistance mutation was developed. The study included an extension analysis using additional collected data of the enrolled patients.

Participant flow — Overall Study
MilestonePatients With EGFR Mutation-positive NSCLC
Started204
Completed98
Not completed106
Withdrew: Patient was followed in another hospital center1
Withdrew: Progressive disease98
Withdrew: Adverse event2
Withdrew: Death5

Outcome measures

PrimaryTime on Treatment With Afatinib (Gi(l)Otrif®) Followed by Osimertinib

Time on treatment, which was defined as time in months from the start date of Afatinib (Gi\[l\]otrif®) treatment ('start date of initial dose' for First-Line Treatment) to the end date of Osimertinib treatment (maximum between 'end date of initial dose' and the last 'end date of dose modification' for Second-Line Treatment) or death date due to any cause ('date of death'). Time on treatment (months) = Time on treatment (days)/30.4375. 'Time on treatment was analysed using Kaplan-Meier method, and the median along with two-sided 90% confidence interval was displayed using the Greenwood's formula for estimation of standard errors.

Time frame:
Data collected from start of treatment until data entry completion, up to 96.8 months for first analysis and up to 114.1 months for the extension analysis.
Reported as:
Median · Months
Time on Treatment With Afatinib (Gi(l)Otrif®) Followed by Osimertinib
MonthsPatients With EGFR Mutation-positive NSCLC
First analysis27.6 (25.9 to 31.3)
Extension analysis27.7 (26.7 to 29.9)
SecondaryThe Percentage of Participants With Different Types of Mutations After Categorisation

Different types of resistance mutations identified at the time of discontinuation of osimertinib treatment were systematically reviewed and categorised.

Time frame:
Data collected from start of treatment until data entry completion; up to 96.8 months.
Reported as:
Number · Percentage of participants (%)
The Percentage of Participants With Different Types of Mutations After Categorisation
Percentage of participants (%)Patients With EGFR Mutation-positive NSCLC
T790M positive69.2
Loss of T790M20.5
T790M positive, loss of sensitizing mutation10.3

Adverse events

Collected over Adverse event information was not applicable for this study, as data were collected retrospectively. The approach was changed for the extension period: Adverse Events were collected from start of data collection once informed consent was signed onwards until the end of data collection, up to 18 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients With EGFR Mutation-positive NSCLC31/203 (15.3%)32/203 (15.8%)62/203 (30.5%)
Most frequent serious events
Most frequent serious events
EventPatients With EGFR Mutation-positive NSCLC
Disease progressionGeneral disorders27/203
DeathGeneral disorders1/203
DiarrhoeaGastrointestinal disorders1/203
SepsisInfections and infestations1/203
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/203
RashSkin and subcutaneous tissue disorders1/203
Most frequent other events
Most frequent other events
EventPatients With EGFR Mutation-positive NSCLC
DiarrhoeaGastrointestinal disorders52/203
RashSkin and subcutaneous tissue disorders34/203
ParonychiaInfections and infestations25/203
StomatitisGastrointestinal disorders21/203
DermatitisSkin and subcutaneous tissue disorders12/203

Baseline characteristics

Full Analysis Set (FAS): FAS included all patients who were enrolled into the study, met all inclusion criteria and did not meet any exclusion criteria and provided a written and signed informed consent (if a written informed consent was required for this NIS by local regulation and legal requirement).

Age, Continuous
Age, Continuous(Years)Patients With EGFR Mutation-positive NSCLC
Mean60.1 ± 10.48
Sex: Female, Male
Sex: Female, Male(Participants)Patients With EGFR Mutation-positive NSCLC
Female110
Male94
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Patients With EGFR Mutation-positive NSCLC
Hispanic or Latino19
Not Hispanic or Latino181
Unknown or Not Reported4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patients With EGFR Mutation-positive NSCLC
American Indian or Alaska Native2
Asian50
Native Hawaiian or Other Pacific Islander1
Black or African American18
White120
More than one race0
Unknown or Not Reported13
08

Study locations

1 site
  • Otto-Wagner Hospital
    Vienna, 1140, Austria
09

References and documents

Publications

  • Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Marten A, Cufer T. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. Future Oncol. 2020 Dec;16(34):2799-2808. doi: 10.2217/fon-2020-0740. Epub 2020 Aug 28. PubMed 32854536 ↗
  • Feinberg B, Halmos B, Gucalp R, Tang W, Moehring B, Hochmair MJ. Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis. Future Oncol. 2020 Aug;16(22):1585-1595. doi: 10.2217/fon-2020-0188. Epub 2020 Aug 6. PubMed 32757853 ↗
  • Yamamoto N, Mera T, Marten A, Hochmair MJ. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib. Adv Ther. 2020 Feb;37(2):759-769. doi: 10.1007/s12325-019-01187-y. Epub 2019 Dec 20. PubMed 31863283 ↗
  • Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Marten A, Cufer T. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol. 2019 Sep;15(25):2905-2914. doi: 10.2217/fon-2019-0346. Epub 2019 Aug 2. PubMed 31370698 ↗
  • Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Golembesky A, Marten A, Cufer T. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol. 2018 Nov;14(27):2861-2874. doi: 10.2217/fon-2018-0711. Epub 2018 Oct 19. PubMed 30336693 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Nov 2019, 23 months.

Results were first posted in Dec 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2017
First posted
Dec 12, 2017
StartActual
Dec 28, 2017
Primary completionActual
Nov 28, 2019
CompletionActual
Nov 28, 2019
Results first posted
Dec 24, 2020
Last update
Dec 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03370770
Responsible party
Sponsor
First posted
Dec 12, 2017
Start date
Dec 28, 2017
Primary completion
Nov 28, 2019
Completion
Nov 28, 2019
Results posted
Dec 24, 2020
Last update
Dec 24, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion